A continuing medical education and nursing continuing professional development activity provided by NAMCP and AAMCN.
This activity is an archive from the live session from the 2025 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.
This activity is valid from March 1, 2026 to March 1, 2027
Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the evaluation and post test. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete it. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate. To print or save your certificate, you will need to click on the "download" button after completing the post test.
Audience: This activity is intended for healthcare professionals practicing in managed care environments.
This activity is supported by an educational grant from
Boehringer Ingelheim
Description:
Fibrosing interstitial lung disease (ILD) refers to a diverse group that describes a broad spectrum of disorders, most of which are characterized by fibrosis or inflammation of the interstitial space between the alveolar epithelium and the capillary endothelium. It is the most common of the idiopathic interstitial pneumonias, and is a devastating disease associated with irreversible destruction of the lung. The condition affects approximately 650,000 people in the US and has a substantial burden to patients, their families, and the overall healthcare system. The management of ILD is multifaceted and involves shared decision making between the healthcare team to provide patient education and support to manage symptoms, treat the disease through individualized treatment strategies, manage comorbidities, and provide palliative care. These treatments focus on managing symptoms, slowing disease progression, and improving quality of life, as there is no cure for the lung damage caused by ILD. Treatment options include oxygen therapy, medications such as corticosteroids and antifibrotics, pulmonary rehabilitation, and in severe cases, lung transplantation. The future is bright for ILD treatment and management as there is a new investigational drug for pulmonary fibrosis, specifically idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It is an oral inhibitor of phosphodiesterase 4B (PDE4B) that has demonstrated positive results in clinical trials. Healthcare professionals should prioritize the opportunity to discuss the ILD guidelines, review data for novel therapies, and emphasize optimal patient selection to access new treatments and improve outcomes.
Upon completion of this activity, participants will be able to:
Faculty:
Mark Yoder, MD
Associate Professor, Medicine
Section Chief, Pulmonary Medicine
Pulmonary, Critical Care & Sleep Medicine
Rush University Medical Center
Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance, independence, objectivity, and scientific rigor in all of their activities. All faculty participating in this activity are required to disclose to NAMCP/AAMCN any financial relationships with ineligible companies. NAMCP/AAMCN in turn discloses all relevant financial conflicts to the learners. NAMCP/AAMCN disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All relevant conflicts of interest have been mitigated prior to the commencement of the activity. See below for conflicts of interest.
Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Yoder has no relevant financial relationships with ineligible companies to disclose.
Planning Committee Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Bill Williams, MD has no relevant financial relationship with an ineligible company to disclose.
Jeremy Williams has no relevant financial relationship with an ineligible company to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationship with an ineligible company to disclose.
NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each physician should claim credit commensurate with the extent of their participation in the activity.
The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.
NAMCP and/or this website do not provide medical advice, diagnosis, or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health-related concern, consult with your physician or healthcare professional.
This activity is supported by an educational grant from
Boehringer Ingelheim
NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.